FLOT is a combination chemotherapy regimen used before surgery in this trial. It includes four different medications that work together to shrink the tumor and make it easier to remove surgically. This regimen is typically used for treating certain types of stomach and esophageal cancers. The goal of using FLOT is to reduce the size of the cancer and improve the chances of a successful surgery.

Standard Adjuvant Chemotherapy is the usual treatment given after surgery to help eliminate any remaining cancer cells and reduce the risk of the cancer coming back. In this trial, it is used as a comparison to see if reducing the amount of chemotherapy (de-escalation) is as effective as the standard approach. This therapy is important for patients who have undergone surgery to ensure that any microscopic cancer cells left behind are treated.

Surveillance is a strategy used in this trial as an alternative to standard chemotherapy after surgery. Instead of receiving additional chemotherapy, patients are closely monitored for any signs of cancer returning. This approach is being tested to see if it can be as effective as standard chemotherapy in patients who are at low risk of their cancer coming back. The goal is to reduce the side effects and burden of treatment while still maintaining good outcomes for the patient.

Gastric Adenocarcinoma – This is a type of cancer that begins in the glandular cells of the stomach lining. It often progresses slowly and may not show symptoms in the early stages. As it advances, it can cause symptoms like stomach pain, nausea, and weight loss. The disease can spread to nearby organs and lymph nodes. It is typically classified based on the depth of tumor invasion and lymph node involvement. Early detection is crucial for managing the disease effectively.

Esophageal Adenocarcinoma – This cancer originates in the cells of the esophagus, particularly in the lower part where it meets the stomach. It is often associated with chronic acid reflux and Barrett’s esophagus. The disease progresses by invading deeper layers of the esophagus and potentially spreading to nearby lymph nodes. Symptoms may include difficulty swallowing, chest pain, and unintended weight loss. The progression is typically assessed by the size and spread of the tumor. Early intervention can help manage the disease’s impact.

Gastroesophageal Junction Adenocarcinoma – This cancer occurs where the esophagus meets the stomach, affecting the cells in this junction area. It shares characteristics with both gastric and esophageal adenocarcinomas. The disease can progress by growing into surrounding tissues and spreading to lymph nodes. Symptoms often include difficulty swallowing, heartburn, and weight loss. The classification of the disease depends on the tumor’s location and extent of spread. Understanding its progression is key to determining appropriate management strategies.